Site Search

Winmostar is an integrated GUI software designed for simulation programs such as GAMESS, MOPAC, LAMMPS, Gromacs, and Quantum ESPRESSO.

What is Winmostar?

Winmostar serves as an integrated software solution, utilizing programs (solvers) for MO, DFT, and MD calculations as its backend. It offers pre- and post-processing capabilities, as well as file and process management functions. The software supports solvers including GAMESS, MOPAC, LAMMPS, Gromacs, and Quantum ESPRESSO. Winmostar is designed to be installed and used on Windows PCs.

For smaller-scale calculations, a single PC can handle the entire operation seamlessly. If needed, you can also leverage resources from cloud platforms or in-house and external high-performance computing systems.

Features

Creation of various atomic and molecular structures
Simple and flexible calculation condition setting
Seamless switching between various computational resources
(local PCs, servers, various clouds)
Automatic management of huge files and processes
Conversion of simulation data
Analysis and visualization of simulation results

What you can do with Winmostar

Efficient and advanced material development

Atomic-scale high-precision simulations enable the visualization of phenomena that are difficult to observe experimentally and the screening of candidate materials.

Perform calculations with a beginner-friendly GUI

More than 45 types of physical properties can be obtained by simple mouse operations.
See Feature List for more details.

Perform practical calculations for professional use

With a variety of features that have supported the research results of 290 organizations for over 20 years,
Winmostar can perform academic paper-level calculations that even frontline researchers can satisfy.
See Feature List for more details.

Implementation achievements/user cases

Winmostar has been introduced to manufacturers, research institutes, and educational institutions such as automobiles, electrical machinery, energy, resources, chemicals, machinery, and pharmaceuticals, and has been cited in 144 papers and patents. The cumulative number of sales is 2012, and the cumulative number of site license implementations is 68. (As of September 26, 2023)

by